Table 3

Specific neutralizing antibody response and protection against challenge with the FMDV A24WT strain after vaccination with commercial polyvalent, A24LL3DYR, or A24LL3BPVKV3DYR chemically inactivated antigen vaccine

TreatmentBovineNeutralization titer (dpv)aProtectionb
071421283542
Commercial vaccine863<0.90.91.21.53.94.23.9Yes
864<0.91.20.9<0.93.63.63.6Yes
865<0.90.90.91.83.93.63.9Yes
866<0.91.21.52.1NDcNDNDND
A24LL3DYR vaccine867<0.92.12.42.73.33.33.0Yes
868<0.92.42.12.73.33.63.9Yes
869<0.92.12.42.73.02.73.0Yes
870<0.92.11.82.43.03.33.0Yes
A24LL 3BPVKV3DYR vaccine1018<0.91.82.12.13.03.33.0Yes
1019<0.92.12.12.13.33.63.0Yes
1020<0.9<0.92.11.82.7NDNDND
1021<0.91.51.82.12.12.73.6Yes
PBS (controls)871<0.9<0.9<0.9<0.92.13.03.6NO
872<0.9<0.9<0.9<0.92.73.33.6NO
1022<0.9<0.9<0.9<0.92.43.32.7NO
1023<0.9<0.9<0.9<0.92.42.72.1NO
  • a dpv, day postvaccination. Day 0 = day of vaccination; day 21 = day of challenge. Virus neutralizing titers of serum antibodies responses (log10 of the reciprocal of the last serum dilution to neutralize 100 TCID50 of virus in 50% of the wells) are shown. Sensitivity, >0.9.

  • b Cattle were challenged by intradermolingual inoculation of 4 log10 bovine infectious doses of FMDV A24WT.

  • c ND, not determined (the animal was euthanized due to an illness unrelated to FMDV).